Vertex Partners With Johnson & Johnson

Vertex Pharmaceuticals (VRTX) entered an agreement with Johnson & Johnson (JNJ) to commercialize and market Vertex's hepatits C medication VX-950. Shares of Vertex jumped $4.68 to close at $36.71 while Johnson & Johnson stock added 3 cents to close at $59.92.